Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FancoMob: CD34+ Mobilization in Fanconi Anemia
NCT02678533Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2017
- Primary completion
- Nov 2018
- Countries
- 1
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Modality
- Small Molecules
- Drugs
- plerixafor
- Conditions
- Fanconi anemia (FA)
01
Overview
Phase 2, open-label, single-arm trial of plerixafor in Fanconi anemia (FA), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: level of CD34+ cells mobilization. Started Feb 2017; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Fanconi anemia
Single arm receiving G-CSF and Plerixafor for mobilization
03
Who it enrols
Patients with Fanconi anemia aged 2-17 years, weighing >10kg, with potential indication for allogenic bone marrow graft but no HLA-identical sibling. Excludes patients with active infection, HIV/HCV, history of cancer or allogeneic graft, or organ failure.
04
Endpoints
Primary
level of CD34+ cells mobilization
Secondary
number of treatment-related adverse events
Beyond the preview
Go deeper on NCT02678533.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02678533.